{"createdAt":"8/2/2020, 2:37:27 PM","timestamp":1596393447263,"Company ID number":"651","DMX_ISSUER_NAME":"YIFAN PHARMACEUTICAL CO.,LTD.","DMX_ISSUER_ID":"IID000000002148555","Country of Classification":"CHINA","name":"Yifan Pharmaceutical Co Ltd ","code":"002019","stock_exchange":"Shenzhen Stock Exchange","people":[{"id":"亿帆医药股份有限公司_程先锋","group":"board","name":"程先锋","title":"董事长,董事","isMale":true,"age":"52","degree":"硕士","salary":"62.40万","stockAmount":"1.303亿","description":"程先锋先生,中国国籍,1968年12月出生,汉族,硕士研究生学历。为公司控股股东、实际控制人。2014年10月至今任亿帆医药股份有限公司董事长,2014年11月至今任亿帆医药股份有限公司总经理,2016年6月至今任健能隆生物医药控股有限公司董事,2016年10月至今任亿帆国际医药有限公司董事,2017年6月至今任亿帆医药(美国)有限公司董事,2018年1月至今任亿帆医药(上海)有限公司董事长,2018年7月至今任亿帆医药(中国香港)有限公司董事,2019年4月至今任北京健能隆生物制药有限公司执行董事。","lastUpdated":"2019-04-26"},{"id":"亿帆医药股份有限公司_冯德崎","group":"board","name":"冯德崎","title":"董事","isMale":true,"age":"41","degree":"硕士","salary":"48.00万","stockAmount":"138万","description":"冯德崎先生,中国国籍,1979年8月出生,汉族,硕士研究生学历。2015年12月至今任沈阳澳华制药有限公司监事,2016年4月至今任亿帆医药股份有限公司董事及董事会秘书,2016年6月至今任健能隆生物医药控股有限公司董事,2016年10月任宁波保税区亿帆医药投资有限公司执行董事、总经理,2016年12月至今任鑫富科技有限公司董事,2017年9月至今任欧芬迈迪(北京)生物技术有限公司执行董事,2017年5月至今任亿帆医药研究院(北京)有限公司执行董事兼总经理。","lastUpdated":"2019-04-26"},{"id":"亿帆医药股份有限公司_林行","group":"board","name":"林行","title":"董事","isMale":true,"age":"34","degree":"硕士","salary":"56.40万","stockAmount":"150万","description":"林行先生,中国国籍,1986年5月出生,汉族,2010年毕业于美国科罗拉多大学,硕士研究生学历。2012年11月至今任亿帆医药股份有限公司副总经理,2015年1月至今任杭州鑫富科技有限公司执行董事,2015年2月至今任安庆市鑫富化工有限责任公司、重庆鑫富化工有限公司、湖州鑫富新材料有限公司执行董事,2016年4月至今任亿帆医药股份有限公司董事,2017年9月至今任杭州鑫富实业科技有限公司执行董事兼总经理。","lastUpdated":"2019-04-26"},{"id":"亿帆医药股份有限公司_周本余","group":"board","name":"周本余","title":"董事","isMale":true,"age":"47","degree":"","salary":"48.00万","stockAmount":"50万","description":"周本余先生,中国国籍,1973年9月出生,汉族,会计师。2014年10月至今任亿帆医药股份有限公司董事,2016年4月至今任亿帆医药股份有限公司审计总监,曾任沈阳志鹰药业有限公司执行董事。","lastUpdated":"2019-04-26"},{"id":"亿帆医药股份有限公司_叶依群","group":"board","name":"叶依群","title":"董事","isMale":true,"age":"47","degree":"本科","salary":"48.00万","stockAmount":"133万","description":"叶依群先生,中国国籍,1973年3月出生,汉族,本科学历,执业药师。2014年10月至今任亿帆医药股份有限公司董事,2015年5月至今任安徽医健投资管理有限公司董事,2015年12月至今任沈阳澳华制药有限公司董事长,2016年3月任西藏恩海百进医药科技有限公司执行董事,2016年6月至今任合肥亿帆生物医药有限公司执行董事,2017年11月至今任沈阳圣元药业有限公司、辽宁圣元药业有限公司执行董事,2018年1月至今任合肥亿帆生物医药有限公司总经理,2019年3月至今任天长亿帆制药有限公司、四川美科制药有限公司、四川德峰药业有限公司执行董事。","lastUpdated":"2019-04-25"},{"id":"亿帆医药股份有限公司_雷新途","group":"board","name":"雷新途","title":"独立董事","isMale":true,"age":"48","degree":"博士","salary":"6.700万","stockAmount":"-","description":"雷新途先生,独立董事候选人,1972年出生,中国国籍,无永久境外居留权。会计学博士、博士后,会计学教授,博士生导师。现担任浙江工业大学会计学研究所所长,会计学科负责人、会计系主任。","lastUpdated":"2019-04-25"},{"id":"亿帆医药股份有限公司_GENHONGCHENG","group":"board","name":"GENHONGCHENG","title":"独立董事","isMale":true,"age":"57","degree":"博士","salary":"6.700万","stockAmount":"-","description":"GENHONG CHENG先生,美国国籍,1963年4月出生,生物学博士研究生学历,教授。1990年在美国纽约AlbertEinstein医学院分子生物学专业获得博士学位,后曾分别在美国洛克菲洛大学和麻省理工学院做博士后研究,导师为诺贝尔奖获得者DavidBaltimore。1996年至今任职美国加州大学洛杉矶分校(UCLA),从事感染,免疫,癌症和代谢等多学科的研究,并先后获得包括美国白血病与淋巴癌学会颁发的斯托尔曼奖等多项科学成就奖,现为加州大学洛杉矶分校微生物与免疫遗传学系终身教授。2000年至今兼任中国科学院生物物理研究所访问教授,2011年至今兼任中国医学科学院协和医科大学兼职教授,负责创建中国医学科学院系统医学研究所,并担任研究所首届所长。2012年被选为美国科学促进会(AAAS)会士,荣获并领导美国国立卫生研究院(NIH)等多个研究机构的20多项研究基金,在国际著名杂志发表论文200余篇,其中大篇分别发表在学术地位最高级的《Nature》和《Science》等杂志上。2006获中科院百人计划奖,2008获国家海外杰出青年奖,2009获“长江学者”奖,2012获“千人计划”奖。","lastUpdated":"2019-04-25"},{"id":"亿帆医药股份有限公司_张克坚","group":"board","name":"张克坚","title":"独立董事","isMale":true,"age":"64","degree":"博士","salary":"10.00万","stockAmount":"-","description":"张克坚先生,1956年4月出生,中国国籍,无境外永久居留权,博士。历任中国医学科学院药物研究所研究员,卫生部临床检验中心室主任,药品审评中心进口药室主任、审评部部长、中心副主任,医疗器械技术审评中心副主任,中山大学药学院教授,广东华南新药创制中心副主任、主任。现任广东华南新药创制中心首席科学家,亿帆医药股份有限公司独立董事,湖南方盛制药股份有限公司独立董事,华润医药集团有限公司(中国香港)独立非执行董事,浙江海翔药业股份有限公司独立董事、辽宁成大生物股份有限公司独立董事、广州朗圣药业有限公司独立董事、合肥医工医药股份有限公司董事。","lastUpdated":"2019-04-25"},{"id":"亿帆医药股份有限公司_许国汉","group":"supervisoryCommittee","name":"许国汉","title":"监事会主席","isMale":true,"age":"53","degree":"","salary":"48.00万","stockAmount":"-","description":"许国汉先生,中国国籍,1967年6月出生,汉族。2018年4月至今任亿帆医药股份有限公司监事会主席,2014年10月至2018年3月任公司副总经理,曾任合肥亿帆生物医药有限公司监事、销售事业部负责人、副总经理、总经理。","lastUpdated":"2019-04-26"},{"id":"亿帆医药股份有限公司_张连春","group":"supervisoryCommittee","name":"张连春","title":"监事","isMale":false,"age":"46","degree":"本科","salary":"48.00万","stockAmount":"-","description":"张连春女士,中国国籍,1974年11月出生,本科学历,工程师。2014年10月至今任亿帆医药股份有限公司监事。亿帆医药股份有限公司总经理助理、公司副总经理、公司审计总监、临安市安全生产监督管理局任综合科科长。","lastUpdated":"2019-04-25"},{"id":"亿帆医药股份有限公司_汪军","group":"supervisoryCommittee","name":"汪军","title":"职工监事","isMale":true,"age":"48","degree":"","salary":"32.83万","stockAmount":"100","description":"汪军先生,中国国籍,1972年2月出生,汉族,教授级高级工程师。2018年3月至今担任公司职工代表监事,2016年4月至今任杭州鑫富科技有限公司副总经理。亿帆医药股份有限公司研发部经理、副总经理,杭州鑫富药业股份有限公司生化分公司总经理等职。","lastUpdated":"2019-04-02"},{"id":"亿帆医药股份有限公司_程先锋","group":"manager","name":"程先锋","title":"总经理","isMale":true,"age":"52","degree":"硕士","salary":"62.40万","stockAmount":"1.303亿","description":"程先锋先生,中国国籍,1968年12月出生,汉族,硕士研究生学历。为公司控股股东、实际控制人。2014年10月至今任亿帆医药股份有限公司董事长,2014年11月至今任亿帆医药股份有限公司总经理,2016年6月至今任健能隆生物医药控股有限公司董事,2016年10月至今任亿帆国际医药有限公司董事,2017年6月至今任亿帆医药(美国)有限公司董事,2018年1月至今任亿帆医药(上海)有限公司董事长,2018年7月至今任亿帆医药(中国香港)有限公司董事,2019年4月至今任北京健能隆生物制药有限公司执行董事。","lastUpdated":"2019-04-26"},{"id":"亿帆医药股份有限公司_冯德崎","group":"manager","name":"冯德崎","title":"董事会秘书","isMale":true,"age":"41","degree":"硕士","salary":"48.00万","stockAmount":"138万","description":"冯德崎先生,中国国籍,1979年8月出生,汉族,硕士研究生学历。2015年12月至今任沈阳澳华制药有限公司监事,2016年4月至今任亿帆医药股份有限公司董事及董事会秘书,2016年6月至今任健能隆生物医药控股有限公司董事,2016年10月任宁波保税区亿帆医药投资有限公司执行董事、总经理,2016年12月至今任鑫富科技有限公司董事,2017年9月至今任欧芬迈迪(北京)生物技术有限公司执行董事,2017年5月至今任亿帆医药研究院(北京)有限公司执行董事兼总经理。","lastUpdated":"2019-04-26"},{"id":"亿帆医药股份有限公司_林行","group":"manager","name":"林行","title":"副总经理","isMale":true,"age":"34","degree":"硕士","salary":"56.40万","stockAmount":"150万","description":"林行先生,中国国籍,1986年5月出生,汉族,2010年毕业于美国科罗拉多大学,硕士研究生学历。2012年11月至今任亿帆医药股份有限公司副总经理,2015年1月至今任杭州鑫富科技有限公司执行董事,2015年2月至今任安庆市鑫富化工有限责任公司、重庆鑫富化工有限公司、湖州鑫富新材料有限公司执行董事,2016年4月至今任亿帆医药股份有限公司董事,2017年9月至今任杭州鑫富实业科技有限公司执行董事兼总经理。","lastUpdated":"2019-04-26"},{"id":"亿帆医药股份有限公司_Huang,Yuliang","group":"manager","name":"Huang,Yuliang","title":"副总经理","isMale":true,"age":"58","degree":"博士","salary":"155.5万","stockAmount":"-","description":"Huang,Yuliang(黄予良),美国国籍,1962年6月出生,化学工程博士研究生学历。2007年9月至今担任DHY&Co.,LTD董事。曾在联邦德国生物科技中心(GBF)任客籍研究员,研究高密度细胞培养及发酵过程自动监控;曾任美国俄亥俄州生物工程研究中心(OBRC)副主任,负责多项项目工艺放大和产业化;也曾在美国EGENCORPORATION任日常管理及其中国分公司任总经理,在任期间顺利完成重组人胰岛素和重组人生长激素在中国的技术转移和药品注册;还曾在HongKongPharmaceuticals(中国香港主板上市企业)任首席科技总监,同时兼任其控股的上海华新生物高技术公司总经理。担任过国家“863”专家评委和上海市科委审评专家,在2014年入选第十一批国家“千人计划”创业类人才计划。为健能隆医药技术(上海)有限公司及DHY&Co.,LTD创始人,曾任健能隆医药技术(上海)有限公司,北京健能隆生物制药有限公司总经理。","lastUpdated":"2019-04-26"},{"id":"亿帆医药股份有限公司_喻海霞","group":"manager","name":"喻海霞","title":"财务总监","isMale":false,"age":"42","degree":"本科","salary":"50.40万","stockAmount":"135万","description":"喻海霞女士,中国国籍,1978年10月出生,本科学历,会计师。2012年11月至今任亿帆医药股份有限公司财务总监。曾任杭州鑫富节能材料有限公司财务经理,公司财务经理。","lastUpdated":"2019-04-26"}],"companyName":"亿帆医药股份有限公司","province":"浙江省","englishName":"Yifan Pharmaceutical Co Ltd","industry":"医药生物 — 化学制药","website":"www.yifanyy.com","mainBusiness":"药品、医药原料药及高分子材料的研发、生产与销售","productsName":["医药产品","医药服务","原料药","高分子材料"],"actualController":"程先锋","actualControllerSharePercentage":"42.14%","registeredCapital":"12.35亿元","employeeAmount":"4295","phone":"86-0551-62672019;86-0551-62652019","location":"浙江省杭州市临安区锦城街道余村村琴山50号","chineseDescription":"亿帆医药股份有限公司是一家集药品、医药原料药及高分子材料研发、生产与销售于一体的创新型企业。主导产品为泛酸系列产品。公司原料药维生素B5及原B5产品70%以上销往欧美等多个国家和地区，全球市场占有率高，居龙头地位。","foundedDate":"2000-11-10","goPublicDate":"2004-07-13","companyHistory":"亿帆医药股份有限公司系经浙江省人民政府企业上市工作领导小组浙上市[2000]37号文批准，在杭州临安生物化学有限公司基础上整体变更设立的股份有限公司，设立时的股东为杭州临安申光贸易有限责任公司、临安博联生物技术有限公司和林关羽、吴彩莲、殷杭华、陈光良、汪军等五位自然人，于2000年11月10日取得浙江省工商行政管理局核发的注册号为【330000000007443】的《企业法人营业执照》。公司股票于2004年7月13日在深圳证券交易所挂牌交易。2005年8月12日实施股权分置改革后公司股票均为流通股。\n　　2014年9月，经中国证监会《关于核准浙江杭州鑫富药业股份有限公司向程先锋等发行股份购买资产的批复》（证监许可[2014]920号）核准，公司实施重大资产重组并同时向程先锋等10名自然人发行21,989.92万股股份。发行完毕后，公司注册资本440,319,243.00元，股份总数440,319,243股（每股面值1元），程先锋持有本公司47.26%的股权，成为本公司的控股股东、实际控制人。2014年11月25日，公司更名为亿帆鑫富药业股份有限公司。\n　　公司第五届董事会第四十次会议、2015年年度股东大会审议通过了《2015年年度利润分配方案》，并于2016年4月28日经公司2015年年度股东大会审议通过，以公司总股本440,319,243股为基数，以资本公积金向全体股东每10股转增15股，权益分派前公司总股本为440,319,243股，权益分派后公司总股本增至1,100,798,107股。公司于2016年5月10日披露了《2015年年度权益分派实施公告》，本次权益分派股权登记日为：2016年5月13日；除权除息日为：2016年5月16日。本次所转股于2016年5月16日直接记入股东证券账户。并委托中国结算深圳分公司代派的现金红利于2016年5月16日通过股东托管证券公司（或其他托管机构）直接划入其资金账户。本次转股完成后，公司的总股本为1,100,798,107股。\n　　截止2019年12月31日，公司注册资本为1,236,904,577.00元。收起▲","shareholders":[{"organizationId":"","holderName":"程先锋","totalShare":"5.21亿","sharePercentage":"42.14%"},{"organizationId":"","holderName":"金元顺安基金-宁波银行-华润深国投信托-华润信托.韶夏增利32号单一资金信托","totalShare":"2123.53万","sharePercentage":"1.72%"},{"organizationId":"","holderName":"中国人寿保险股份有限公司-分红-个人分红-005L-FH002深","totalShare":"1428.17万","sharePercentage":"1.15%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"1251.07万","sharePercentage":"1.01%"},{"organizationId":"T000138941","holderName":"青岛海尔创业投资有限责任公司","totalShare":"1171.05万","sharePercentage":"0.95%"},{"organizationId":"T000392646","holderName":"江苏一带一路投资基金(有限合伙)","totalShare":"1061.76万","sharePercentage":"0.86%"},{"organizationId":"T004755867","holderName":"深圳国调招商并购股权投资基金合伙企业(有限合伙)","totalShare":"1061.76万","sharePercentage":"0.86%"},{"organizationId":"T004456768","holderName":"安徽中安健康投资管理有限公司-安徽省中安健康养老服务产业投资合伙企业(有限合伙)","totalShare":"1061.76万","sharePercentage":"0.86%"},{"organizationId":"","holderName":"姜维平","totalShare":"802.53万","sharePercentage":"0.65%"},{"organizationId":"","holderName":"黄小敏","totalShare":"771.11万","sharePercentage":"0.62%"},{"organizationId":"","holderName":"中国农业银行股份有限公司-中证500交易型开放式指数证券投资基金","totalShare":"731.81万","sharePercentage":"0.59%"},{"organizationId":"00009270","holderName":"兴业证券股份有限公司","totalShare":"660.00万","sharePercentage":"0.53%"}],"englishDescription":"YIFAN XINFU PHARMACEUTICAL CO.,LTD, is a China-based company primarily engaged in production and sale of polymer materials. The Company operates in three segments, including Pharmaceuticals, Pharmaceutical Raw Material and Intermediates, as well as Polymer Materials. The Company's main products include D-calcium pantothenate, D- panthenol, poly butylenes succinate and others. The Company distributes its products in domestic and overseas markets.","englishIndustry":"Biotechnology & Drugs","Price to earnings (ttm)":"33.67","Price to sales (ttm)":"6.79","Price to book (mrq)":"4.55","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"27.10","Lt debt to equity (mrq)":"2.21","Return on investment (ttm)":"13.64","Return on equity (ttm)":"9.84","Income statement":{"Revenue":"5,186.84","Total revenue":"5,186.84","Cost of revenue, total":"2,794.11","Gross profit":"2,392.73","Selling/general/admin. expenses, total":"1,038.59","Research & development":"202.13","Depreciation/amortization":"82.45","Interest exp.(inc.),net-operating, total":"46.83","Unusual expense (income)":"84.68","Other operating expenses, total":"(137.99)","Total operating expense":"4,110.80","Operating income":"1,076.04","Other, net":"(7.85)","Net income before taxes":"1,068.19","Provision for income taxes":"195.07","Net income after taxes":"873.12","Minority interest":"30.35","Net income before extra. items":"903.47","Net income":"903.47","Income available to com excl extraord":"903.47","Income available to com incl extraord":"903.47","Diluted net income":"903.47","Diluted weighted average shares":"1,236.90","Diluted eps excluding extraord items":"0.73","Dps - common stock primary issue":"0.10","Diluted normalized eps":"0.79","Gain (loss) on sale of assets":"(4.60)"},"Balance sheet":{"Cash":"0.13","Cash & equivalents":"921.71","Short term investments":"39.00","Cash and short term investments":"960.85","Accounts receivable - trade, net":"945.29","Total receivables, net":"1,212.35","Total inventory":"598.19","Prepaid expenses":"147.12","Other current assets, total":"601.82","Total current assets":"3,520.32","Property/plant/equipment, total - gross":"2,224.02","Accumulated depreciation, total":"(934.98)","Property/plant/equipment, total - net":"1,289.04","Goodwill, net":"2,727.68","Intangibles, net":"2,583.57","Long term investments":"731.05","Other long term assets, total":"214.14","Total assets":"11,065.80","Accounts payable":"398.58","Accrued expenses":"103.03","Notes payable/short term debt":"1,804.83","Current port. of  lt debt/capital leases":"41.93","Other current liabilities, total":"534.94","Total current liabilities":"2,883.32","Long term debt":"83.97","Total long term debt":"83.97","Total debt":"1,930.73","Deferred income tax":"211.98","Minority interest":"322.14","Other liabilities, total":"64.83","Total liabilities":"3,566.24","Common stock, total":"1,057.20","Additional paid-in capital":"2,953.00","Retained earnings (accumulated deficit)":"3,690.02","Treasury stock - common":"(199.33)","Other equity, total":"(1.32)","Total equity":"7,499.56","Total liabilities & shareholders' equity":"11,065.80","Total common shares outstanding":"1,210.83","Tangible book value per share, common eq":"1.81"},"Cash flow":{"Cash receipts":"5,305.71","Cash payments":"(2,804.81)","Cash taxes paid":"(451.41)","Changes in working capital":"(1,112.26)","Cash from operating activities":"937.24","Capital expenditures":"(866.07)","Other investing cash flow items, total":"(720.39)","Cash from investing activities":"(1,586.46)","Financing cash flow items":"(131.51)","Total cash dividends paid":"(192.34)","Issuance (retirement) of debt, net":"474.94","Cash from financing activities":"151.09","Foreign exchange effects":"9.58","Net change in cash":"(488.55)"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"29.55","52 Week High":"32.19","52 Week Low":"9.89","Pricing date":"","10 Day Average Trading Volume":"35.86","Market Capitalization":"36,484.71","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"639.29","Beta":"1.11","1 Day Price Change":"-0.24","13 Week Price Return (Daily)":"58.28","26 Week Price Return (Daily)":"65.08","5 Day Price Return (Daily)":"1.83","52 Week Price Return (Daily)":"163.84","Year To Date Price Return (Daily)":"81.85","Month to Date Price Return (Daily)":"28.65","Price Relative to S&P500 (4 Week)":"10.32","Price Relative to S&P500 (13 Week)":"24.43","Price Relative to S&P500 (26 Week)":"29.30","Price Relative to S&P500 (52 Week)":"79.30","Price Relative to S&P500 (YTD)":"39.08"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.73","EPS excl. Extra Items (TTM)":"0.88","EPS Normalized (Annual)":"0.79","Revenue per Share (Annual)":"4.19","Revenue per Share (TTM)":"4.37","Book Value (Per Share Annual)":"6.19","Book Value (Per Share Quarterly)":"6.49","Tangible Book Value (Per Share Annual)":"1.81","Tangible Book Value (Per Share Quarterly)":"2.07","Cash Per Share (Per Share Annual)":"0.79","Cash Per Share (Per Share Quarterly)":"1.49","Cash Flow (Per Share Annual)":"0.83","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.10","Dividends (Per Share TTM)":"0.10","EBITD (Per Share TTM)":"1.09","EPS Basic excl. Extra Items (Annual)":"0.73","EPS Basic excl. Extra Items (TTM)":"0.88","EPS incl. Extra Items (Annual)":"0.73","EPS incl. Extra Items (TTM)":"0.88","Free Cash Flow (Per Share TTM)":"0.06","Dividend (Per Share 5Y)":"0.16"},"Valuation":{"P/E excl. Extra Items (Annual)":"40.46","P/E excl. Extra Items (TTM)":"33.67","P/E Normalized (Annual)":"37.58","Price to sales (Annual)":"7.03","Price to sales (TTM)":"6.79","Price to Tangible Book (Annual)":"16.67","Price to Tangible Book (Quarterly)":"14.55","Price to Free Cash Flow (Per Share Annual)":"--","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"529.24","Price to Book (Annual)":"4.77","Price to Book (Quarterly)":"4.55","P/E Basic excl. Extra Items (TTM)":"18.57","P/E excl. Extra Items High (TTM)":"33.94","P/E excl. Extra Items Low (TTM)":"12.49","P/E incl. Extra Items (TTM)":"33.67","Net Debt (Interim)":"321.27","Net Debt (Annual)":"969.89","Dividend Yield (5Y)":"0.97","Dividend Yield":"0.34","Current Dividend Yield (TTM)":"0.34"},"Financial Strength":{"Free Cash Flow (Annual)":"-121.17","Current Ratio (Annual)":"1.22","Net Interest coverage (Annual)":"25.79","Long Term Debt/Equity (Annual)":"1.12","Payout Ratio (Annual)":"13.69","Quick Ratio (Annual)":"1.01","Total Debt/Total Equity (Annual)":"25.74","Current EV/Free Cash Flow (Annual)":"--","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"1.33","Long Term Debt/Equity (Quarterly)":"2.21","Quick Ratio (Quarterly)":"1.13","Total Debt/Total Equity (Quarterly)":"27.10","Free Cash Flow (TTM)":"68.94","Net Interest Coverage (TTM)":"--","Payout Ratio (TTM)":"11.46"},"Margins":{"Gross Margin (Annual)":"46.13","Gross Margin (TTM)":"48.54","Net Profit Margin % (Annual)":"16.83","Net Profit Margin (TTM)":"19.49","Operating Margin (Annual)":"20.75","Operating Margin (TTM)":"23.67","Pretax Margin (TTM)":"23.50","Pretax Margin (Annual)":"20.59","Operating Margin (5Y)":"23.53","Pretax Margin (5Y)":"23.95","Free Operating Cash Flow/Revenue (5Y)":"4.17","Free Operating Cash Flow/Revenue (TTM)":"1.28","Gross Margin (5Y)":"48.14","Net Profit Margin (5Y)":"19.26"},"Management Effectiveness":{"Return on Assets (Annual)":"8.38","Return on Equity (TTM)":"9.84","Return on Average Equity (Annual)":"12.79","Return on Average equity (TTM)":"14.76","Return on Investment (Annual)":"11.66","Return on Investment (TTM)":"13.64","Return on Average Assets (5Y)":"10.40","Return on Average Equity (5Y)":"16.37","Return on Investment (5Y)":"14.72","Asset Turnover (Annual)":"0.50","Asset Turnover (TTM)":"0.50","Inventory Turnover (Annual)":"5.19","Inventory Turnover (TTM)":"5.01","Net Income/Employee (Annual)":"204,836.60","Net Income/Employee (TTM)":"243,905.30","Receivables Turnover (Annual)":"5.64","Receivables Turnover (TTM)":"4.99","Revenue/Employee (Annual)":"1,216,855.00","Revenue/Employee (TTM)":"1,251,600.00"},"Growth":{"Revenue Growth (Quarterly YoY)":"16.62","Revenue Growth Rate (5Y)":"25.22","EPS Growth (Quarterly YoY)":"113.25","EPS Growth (TTM YoY)":"89.37","EPS Growth Rate (5Y)":"14.87","Dividend Growth Rate (3Y)":"0.00","Revenue Growth (TTM YoY)":"19.07","Revenue Growth (Per Share 5Y)":"10.15","Revenue Growth Rate (3Y)":"13.96","EPS Growth Rate (3Y)":"4.49","Book Value Growth Rate (Per Share 5Y)":"21.79","Tangible Book Value Total Equity CAGR (5Y)":"13.59","Capital Spending growth rate 5 year":"57.45","EBITDA CAGR (5Y)":"33.13","EBITDA Interim CAGR (5Y)":"29.37","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"34.86","Net Profit Margin Growth Rate (5Y)":"3.58"},"Income Statement":{"Revenue (Annual)":"5,186.84","Revenue (TTM)":"5,375.62","EBITD (Annual)":"1,360.13","EBITD (TTM)":"1,347.10","Earnings Before Taxes (Annual)":"1,068.19","Earnings Before Taxes (TTM)":"1,263.01","Net Income to Common (Annual)":"903.47","Net Income to Common (TTM)":"1,079.74","Earnings Before Taxes Normalized (Annual)":"1,152.87","Net Income Available to Common Normalized (Annual)":"972.68","Diluted Normalized EPS excl. Extra Items (TTM)":"0.93"}}}